spindle cell tumors
Reading Document
Medical Text Search
spindle cell tumors classification histopathology diagnosis
Medical Text Search
spindle cell neoplasms differential diagnosis immunohistochemistry
Medical Image Search
spindle cell tumor histology microscopy
GradeResponse
GradeResponse
GradeResponse
Spindle Cell Tumors
Spindle cell tumors are a broad category of neoplasms characterized by elongated, fusiform (spindle-shaped) cells on histology. They span benign to malignant entities and arise from diverse cell lineages — mesenchymal, epithelial, melanocytic, and neural.
Histologic Appearance
The hallmark is elongated cells with oval-to-tapering nuclei arranged in fascicles, whorls, or storiform (cartwheel) patterns. Assessing mitotic activity, nuclear pleomorphism, necrosis, and architectural pattern is critical to grading.
Classification by Cell of Origin
| Category | Key Tumors | Malignant Counterpart |
|---|---|---|
| Fibroblastic/Myofibroblastic | Nodular fasciitis, desmoid fibromatosis, DFSP | Fibrosarcoma, myofibrosarcoma |
| Smooth muscle | Leiomyoma | Leiomyosarcoma |
| Peripheral nerve sheath | Neurofibroma, schwannoma | MPNST |
| GI stromal (GIST) | Benign GIST | Malignant GIST |
| Vascular | Spindle cell hemangioma | Angiosarcoma, Kaposi sarcoma |
| Melanocytic | — | Spindle cell melanoma, desmoplastic melanoma |
| Epithelial | — | Spindle cell carcinoma, sarcomatoid carcinoma |
| Thyroid | — | Anaplastic thyroid carcinoma (spindle cell variant) |
| Mixed/Other | Synovial sarcoma | Biphasic/monophasic synovial sarcoma |
Key Entities in Detail
1. GIST (Gastrointestinal Stromal Tumor)
The most common mesenchymal tumor of the GI tract. Per Harrison's (p. 2463):
- Histology: Spindle cell subtype ~70%; epithelioid ~20%; mixed ~10%
- IHC: c-kit (CD117) and CD34 positivity; mutational analysis of cKIT and PDGFRA required in all cases
- Treatment:
- Localized: laparoscopic wedge/segmental resection (lymphadenectomy not needed)
- High-risk/metastatic: imatinib (c-kit tyrosine kinase inhibitor) for cKIT-mutated tumors
- Prognosis determinants: tumor size + mitotic index (not histology or mutation type alone)
2. Dermatofibrosarcoma Protuberans (DFSP)
- Low-grade fibroblastic sarcoma of the dermis/subcutis
- Storiform pattern; CD34+, factor XIIIa−
- Characteristic COL1A1-PDGFB translocation t(17;22)
- Low metastatic potential but high local recurrence; imatinib used for unresectable disease
3. Leiomyosarcoma
- Smooth muscle origin; intersecting fascicles of cells with "cigar-shaped" nuclei
- IHC: SMA+, desmin+, h-caldesmon+
- Common sites: uterus, retroperitoneum, vascular wall
- Graded by FNCLCC system; prognosis depends on grade and site
4. Malignant Peripheral Nerve Sheath Tumor (MPNST)
- Often arises in NF1 patients (50%) or sporadically
- IHC: S100+ (only ~50%), SOX10+, loss of H3K27me3 (trimethylation) — sensitive/specific marker
- High-grade; wide excision ± radiation; poor response to chemotherapy
5. Synovial Sarcoma
- Despite name, not of synovial origin; arises near joints in young adults
- Monophasic (pure spindle) or biphasic (spindle + epithelial glands)
- Cytogenetics: t(X;18)(p11;q11) → SS18-SSX fusion (diagnostic)
- IHC: TLE1+, EMA+, CK+; CD34−, S100−
- Chemosensitive (ifosfamide-based regimens)
6. Spindle Cell / Desmoplastic Melanoma
- Rare, arises on sun-damaged skin (head/neck)
- Mimics sarcoma or nerve sheath tumor
- IHC: S100+++ (strong), SOX10+; HMB-45 and Melan-A often negative (pitfall)
- Surgery is primary treatment; immunotherapy effective for metastatic disease
7. Anaplastic Thyroid Carcinoma (Spindle Cell Variant)
- Rapidly progressive, lethal; typically in elderly patients with large neck masses
- Diagnosis confirmed histologically (exclude lymphoma, MALT, medullary carcinoma — all more treatable) per Anaplastic Thyroid Cancer Update (p. 9)
- IHC: variable; often p53+, loss of TTF-1; cytokeratin focally positive
- Multi-modal approach (surgery + EBRT + systemic therapy); median survival ~5 months
Immunohistochemistry Panel for Differential Diagnosis
| Marker | Fibroblastic | Smooth Muscle | GIST | Neural | Melanoma | Synovial Sarcoma | Carcinoma |
|---|---|---|---|---|---|---|---|
| CD117 (c-kit) | − | − | + | − | − | − | − |
| CD34 | +/− | − | + | − | − | − | − |
| SMA | +/− | + | − | − | − | − | − |
| S100 | − | − | − | + | + | − | − |
| TLE1 | − | − | − | − | − | + | − |
| CK/EMA | − | − | − | − | − | +/− | + |
| HMB-45 | − | − | − | − | +/− | − | − |
Diagnostic Approach
- Core needle biopsy (preferred over FNA for soft tissue masses)
- H&E morphology → architecture, mitoses, necrosis, pleomorphism
- IHC panel tailored to morphologic differential
- Molecular/cytogenetic testing when IHC is ambiguous:
- FISH or RT-PCR for SS18-SSX (synovial sarcoma)
- PDGFB rearrangement (DFSP)
- cKIT/PDGFRA sequencing (GIST)
- H3K27me3 loss by IHC (MPNST)
- Staging imaging: MRI for local extent, CT chest/abdomen/pelvis for metastases
General Management Principles
- Surgery: mainstay for localized disease; wide negative margins critical
- Radiation: adjuvant for high-grade or close/positive margins (especially extremity sarcomas)
- Chemotherapy: most sarcomas have limited chemo-sensitivity; exceptions include synovial sarcoma, rhabdomyosarcoma, Ewing sarcoma
- Targeted therapy: imatinib/sunitinib (GIST), imatinib (DFSP with PDGFB fusion), dabrafenib+trametinib (BRAF-mutated anaplastic thyroid ca)
- Immunotherapy: effective in desmoplastic melanoma
The key to spindle cell tumor diagnosis is integrating morphology, IHC, and molecular findings — no single stain is sufficient, and clinical context (age, site, size, growth rate) remains indispensable.
This is a shared conversation. Sign in to Orris to start your own chat.